Pari Pharma GmbH   Report issue

For profit Phase 1 Phase 3
Founded: Starnberg Germany (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2009
NCT01334892
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Pari Pharma GmbH

Active Ingredients

Drugs in Phase 3 Trials (2)

budesonide (rhinocort) (2 trials)

cyclosporine (sandimmune) (1 trial)

Drugs in Phase 1 Trials (2)

teicoplanin (1 trial)

tobramycin (nebcin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchiolitis (Phase 3)

Bronchiolitis Obliterans (Phase 3)

Colorectal Neoplasms (Phase 3)

Cystic Fibrosis (Phase 1)

Fibrosis (Phase 1)

Nasopharyngeal Neoplasms (Phase 3)

Sinusitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4